Skip to Content

Olopatadine (Ophthalmic)

Medically reviewed by Last updated on Jul 20, 2019.


(oh la PAT a deen)

Index Terms

  • Olopadadine HCl
  • Olopatadine Hydrochloride

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Ophthalmic:

Pataday: 0.2% (2.5 mL) [contains benzalkonium chloride, edetate disodium]

Patanol: 0.1% (5 mL) [contains benzalkonium chloride]

Pazeo: 0.7% (2.5 mL) [contains benzalkonium chloride]

Generic: 0.1% (5 mL); 0.2% (2.5 mL)

Brand Names: U.S.

  • Pataday
  • Patanol
  • Pazeo

Pharmacologic Category

  • Histamine H1 Antagonist
  • Histamine H1 Antagonist, Second Generation
  • Piperidine Derivative


Selective histamine H1-antagonist; inhibits release of histamine from mast cells. Inhibits histamine induced effects on conjunctival epithelial cells.


Low systemic absorption


Not extensively metabolized


Urine (60% to 70%, mostly as unchanged drug); feces (17%)

Half-Life Elimination

~3 hours

Protein Binding

~55% (primarily albumin)

Use: Labeled Indications

Allergic conjunctivitis: Treatment of ocular itching associated with allergic conjunctivitis


Patanol: Hypersensitivity to olopatadine hydrochloride or any component of the formulation.

Pataday, Pazeo: There are no contraindications listed in the manufacturer's labeling.

Canadian labeling (Pataday, Pazeo): Additional contraindications (not in the US labeling): Hypersensitivity to olopatadine or any component of the formulation.

Dosing: Adult

Allergic conjunctivitis: Ophthalmic:

Pataday, Pazeo: Instill 1 drop into each affected eye once daily

Patanol: Instill 1 drop into each affected eye twice daily (allowing 6 to 8 hours between doses)

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Allergic conjunctivitis: Ophthalmic:

Pataday, Pazeo: Children ≥2 years and Adolescents: Refer to adult dosing.

Patanol: Children ≥3 years and Adolescents: Refer to adult dosing.


For topical ophthalmic use only. Wash hands prior to use. Do not touch tip of container to eye. After instilling drops, wait at least 5 to 10 minutes before inserting contact lenses. Do not insert contacts if eyes are red.


Store at 2°C to 25°C (36°F to 77°F).

Drug Interactions

There are no known significant interactions.

Adverse Reactions

Central nervous system: Headache (≤5%)

Gastrointestinal: Dysgeusia (2% to 5%), nausea (≤5%)

Infection: Cold symptoms (≤10%)

Neuromuscular & skeletal: Back pain (≤5%), weakness (≤5%)

Ocular: Abnormal sensation in eyes (2% to 5%), blurred vision (2% to 5%), dry eye syndrome (2% to 5%), superficial punctate keratitis (2% to 5%), burning sensation of eyes (≤5%), conjunctivitis (≤5%), eyelid edema (≤5%), eye pain (≤5%), eye pruritus (≤5%), foreign body sensation (≤5%), keratitis (≤5%), stinging of eyes (≤5%), hyperemia

Respiratory: Pharyngitis (≤10%), cough (≤5%), rhinitis (≤5%), sinusitis (≤5%)

Miscellaneous: Flu-like symptoms (≤5%), hypersensitivity (≤5%), infection (≤5%)


Other warnings/precautions:

• Contact lens: Not for use to treat contact lens-related irritation. Solution contains benzalkonium chloride; remove lens prior to administration and wait at least 10 minutes before reinserting. Do not use contact lenses if eyes are red.

Pregnancy Risk Factor


Pregnancy Considerations

Olopatadine has minimal systemic absorption following ophthalmic administration. Systemic absorption would be required in order for olopatadine to cross the placenta and reach the fetus.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience signs of common cold, blurred vision, foreign body sensation in eye, dry eyes, change in taste, or headache. Have patient report immediately to prescriber vision changes, eye pain, or severe eye irritation (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.